BioCentury
ARTICLE | Product R&D

Tusk’s take on CD25

How Tusk is bringing CD25 mAbs back into cancer

June 21, 2018 11:59 PM UTC

As companies revisit the potential of IL-2 to aid cancer immunotherapy, Tusk Therapeutics Ltd. has a new take by attacking CD25, a component of the IL-2 receptor with its own storied past. Its antibody could overcome both histories by uncoupling the helpful and harmful effects of IL-2.

The problem has been that IL-2 receptors exist on both effector T cells and immunosuppressive Tregs, which means either activating or blocking them both stimulates and suppresses the immune system...